AI In Drug Repurposing Market Size, Share & Trends Analysis Report By Component (Software & Platform, Services), By Technology (Machine Learning Algorithms, Generative AI & Large Language Models), By Application (Oncology, Rare & Orphan Diseases), By End

AI In Drug Repurposing Market Summary

The global AI in drug repurposing market size was estimated at USD 1.02 billion in 2024 and is projected to reach USD 5.48 billion by 2033, growing at a CAGR of 20.39% from 2025 to 2033. Rising demand for cost-effective drug development, advancements in AI algorithms, and the growing prevalence of rare and complex diseases are significant factors contributing to market growth.

In addition, increasing collaborations between pharmaceutical companies, academic institutions, and AI technology providers, and improvements in computing power and cloud infrastructure are some other factors fueling the growth.

The rising demand for cost-effective drug development strategies substantially drives the growth of the AI in drug repurposing industry. Traditional drug discovery involves lengthy timelines, often exceeding a decade, and costs frequently exceed USD 2 billion per drug. Drug repurposing offers a strategy to bypass early-stage safety testing by focusing on approved or investigational drugs for new indications. AI accelerates this process by rapidly analyzing extensive biological, chemical, and clinical datasets to identify novel drug-disease associations. This reduces development timelines and costs, offering pharmaceutical companies and healthcare providers an economically viable alternative to de novo drug development. Integrating artificial intelligence with drug repurposing effectively addresses key industry challenges by enhancing productivity while reducing associated risks and investments.

AI systems integrate multi-omics data, including genomics, proteomics, and metabolomics, with biomedical literature and real-world patient records to identify subtle and previously unrecognized drug-target interactions. These methods enable the identification of polypharmacology candidates and synergistic drug combinations, overcoming limitations of traditional hypothesis-driven discovery. For instance, in April 2025, Plex Research partnered with Ginkgo Bioworks to use AI-powered analysis on the GDPx2 dataset, a large transcriptomics survey of compound-induced gene expression. This collaboration aims to identify novel disease mechanisms, discover new therapeutic applications, and accelerate drug repurposing, linking findings with experimental data for rigorous validation.

Furthermore, the rising prevalence of rare diseases propels market growth further. For instance, according to the data published by The Lancet Journal in March 2024, around 300 million people live with rare diseases, affecting around 3.5% - 5.9% of the global population. Moreover, around 80% of rare diseases are genetically caused, almost 70% of which are present in childhood. AI facilitates the analysis of limited datasets from rare disease cohorts, enabling the identification of therapeutic candidates from existing drugs, thus expediting treatment access.

Global AI In Drug Repurposing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AI in drug repurposing market report based on component, technology, application, end use, and region:

• Component Outlook (Revenue, USD Million, 2021 - 2033)
• Software & Platforms
• Services
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Machine Learning/Deep Learning
• Natural Language Processing (NLP)
• Knowledge Graphs & Network-Based AI
• Generative AI & Large Language Models (LLMs)
• Computer Vision
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Rare & Orphan Diseases
• Other Therapeutic Areas
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• MEA
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 4-8 business days upon order notification. Show more